{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:42Z","timestamp":1790931342710,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Technische Universit\u00e4t M\u00fcnchen","id":[{"id":"https:\/\/ror.org\/02kkvpp62","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>In patients with liver-dominant metastatic disease undergoing yttrium-90 (\u2079\u2070Y) transarterial radioembolization (TARE), response assessment remains challenging, particularly in multifocal disease where manual RECIST-based measurements may not adequately reflect overall hepatic tumor burden. In addition, the prognostic relevance of volumetric changes in tumor, liver, and spleen after TARE remains unclear. This retrospective study evaluated automated CT-based whole-liver tumor volumetry as a quantitative imaging biomarker for response assessment and progression risk stratification following TARE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed imaging and clinical data from 57 adults with liver-dominant metastatic disease (colorectal, neuroendocrine, uveal melanoma, and breast cancer) treated with yttrium-90 (\u2079\u2070Y) resin TARE between January 2012 and December 2022. Inclusion criteria were age\u2009\u2265\u200918 years, availability of baseline contrast-enhanced CT imaging, and clinical follow-up. Patients undergoing liver resection, transplantation, or additional locoregional therapies during follow-up were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline tumor volume was a strong independent predictor of progression-free survival (PFS), demonstrating excellent discriminatory performance (ROC-AUC 0.91; 95% CI 0.82\u20131.00). A threshold of 270 mL most accurately identified early progression (&lt;\u200912 months), with a sensitivity of 0.84 and specificity of 0.92. In contrast, lesion count, embolization strategy, and maximum tumor diameter were not significantly associated with PFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Automated baseline tumor volumetry demonstrated promising prognostic performance compared with conventional clinical and procedural parameters in patients with liver-dominant metastases treated with \u2079\u2070Y TARE. Automated quantification of intrahepatic tumor burden may serve as a useful and readily accessible imaging biomarker for early risk stratification, although external validation is required before clinical implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08051-6","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:11:25Z","timestamp":1783145485000},"page":"6955-6965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AI-based tumor and organ volumetry predicts early progression after Y-90 radioembolization in liver-dominant metastatic disease"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5169-2393","authenticated-orcid":false,"given":"Daniel","family":"Martinez Heinemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannis","family":"Bodden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Endroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felianty","family":"Teresa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Mergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Spitzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Martignoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kirschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rickmer","family":"Braren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Steinhelfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"5","key":"8051_CR1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1055\/s-0040-1719189","volume":"37","author":"C O\u2019Leary","year":"2020","unstructured":"O\u2019Leary C, Soulen MC, Shamimi-Noori S. Interventional oncology approach to hepatic metastases. Semin Intervent Radiol. 2020;37(5):484\u201391. https:\/\/doi.org\/10.1055\/s-0040-1719189.","journal-title":"Semin Intervent Radiol"},{"issue":"12","key":"8051_CR2","doi-asserted-by":"publisher","first-page":"e2550467","DOI":"10.1001\/jamanetworkopen.2025.50467","volume":"8","author":"IR Johannsen","year":"2025","unstructured":"Johannsen IR, Boysen AK, Nielsen MF, Mortensen FV, Kirkeg\u00e5rd J. Liver metastases and survival among patients with colorectal cancer. JAMA Netw Open. 2025;8(12):e2550467. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.50467.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"8051_CR3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.5306\/wjco.v12.i9.725","volume":"12","author":"KE Zane","year":"2021","unstructured":"Zane KE, Cloyd JM, Mumtaz KS, Wadhwa V, Makary MS. Metastatic disease to the liver: locoregional therapy strategies and outcomes. World J Clin Oncol. 2021;12(9):725\u201345. https:\/\/doi.org\/10.5306\/wjco.v12.i9.725.","journal-title":"World J Clin Oncol"},{"issue":"5","key":"8051_CR4","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, Lam M, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49(5):1682\u201399. https:\/\/doi.org\/10.1007\/s00259-021-05600-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"8051_CR5","doi-asserted-by":"publisher","first-page":"10325","DOI":"10.3390\/curroncol30120752","volume":"30","author":"SG Thoduka","year":"2023","unstructured":"Thoduka SG, Flegar L, Groeben C, et al. Trends in Selective Internal Radiation Therapy (SIRT) for treating hepatocellular carcinoma, cholangiocarcinoma, and liver metastasis: a total population analysis from 2006 to 2021 in Germany. Curr Oncol. 2023;30(12):10325\u201335. https:\/\/doi.org\/10.3390\/curroncol30120752. Published 2023 Dec 5.","journal-title":"Curr Oncol"},{"issue":"9","key":"8051_CR6","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","volume":"18","author":"HS Wasan","year":"2017","unstructured":"Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(17)30457-6.","journal-title":"Lancet Oncol"},{"issue":"9","key":"8051_CR7","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.2967\/jnumed.113.135855","volume":"55","author":"Z Devcic","year":"2014","unstructured":"Devcic Z, Rosenberg J, Braat AJ, et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med. 2014;55(9):1404\u201310. https:\/\/doi.org\/10.2967\/jnumed.113.135855.","journal-title":"J Nucl Med"},{"issue":"2","key":"8051_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00270-019-02366-8","volume":"43","author":"AO Levey","year":"2020","unstructured":"Levey AO, Elsayed M, Lawson DH, et al. Predictors of overall and progression-free survival in patients with ocular melanoma metastatic to the liver undergoing y90 radioembolization. Cardiovasc Intervent Radiol. 2020;43(2):254\u201363. https:\/\/doi.org\/10.1007\/s00270-019-02366-8.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"8051_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4251\/wjgo.v12.i2.228","volume":"12","author":"M Feretis","year":"2020","unstructured":"Feretis M, Solodkyy A. Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review. World J Gastrointest Oncol. 2020;12(2):228\u201336. https:\/\/doi.org\/10.4251\/wjgo.v12.i2.228.","journal-title":"World J Gastrointest Oncol"},{"issue":"9","key":"8051_CR10","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.jvir.2016.06.016","volume":"27","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Salem R, Lewandowski RJ. Yttrium-90 radioembolization for breast cancer liver metastases. J Vasc Interv Radiol. 2016;27(9):1316\u20139. https:\/\/doi.org\/10.1016\/j.jvir.2016.06.016.","journal-title":"J Vasc Interv Radiol"},{"issue":"7","key":"8051_CR11","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/cncr.23339","volume":"112","author":"B Sangro","year":"2008","unstructured":"Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112(7):1538\u201346. https:\/\/doi.org\/10.1002\/cncr.23339.","journal-title":"Cancer"},{"issue":"3","key":"8051_CR12","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/hep.26191","volume":"57","author":"B Gil-Alzugaray","year":"2013","unstructured":"Gil-Alzugaray B, Chopitea A, I\u00f1arrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology. 2013;57(3):1078\u201387. https:\/\/doi.org\/10.1002\/hep.26191.","journal-title":"Hepatology"},{"issue":"2","key":"8051_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"8","key":"8051_CR14","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jvir.2018.02.020","volume":"29","author":"AA Weiner","year":"2018","unstructured":"Weiner AA, Gui B, Newman NB, et al. Predictors of survival after Yttrium-90 radioembolization for colorectal cancer liver metastases. J Vasc Interv Radiol. 2018;29(8):1094\u2013100. https:\/\/doi.org\/10.1016\/j.jvir.2018.02.020.","journal-title":"J Vasc Interv Radiol"},{"key":"8051_CR15","doi-asserted-by":"publisher","unstructured":"Steinhelfer L, Jungmann F, Endroes L, et al. Fully automated spleen segmentation predicts progression-free survival in HCC patients following transarterial radioembolization. Eur J Nucl Med Mol Imaging. 2026;53(6):3904\u201314. https:\/\/doi.org\/10.1007\/s00259-026-07792-8.","DOI":"10.1007\/s00259-026-07792-8"},{"issue":"8","key":"8051_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41568-018-0016-5","volume":"18","author":"A Hosny","year":"2018","unstructured":"Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL. Artificial intelligence in radiology. Nat Rev Cancer. 2018;18(8):500\u201310. https:\/\/doi.org\/10.1038\/s41568-018-0016-5.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"8051_CR17","doi-asserted-by":"publisher","first-page":"e230024","DOI":"10.1148\/ryai.230024","volume":"5","author":"J Wasserthal","year":"2023","unstructured":"Wasserthal J, Breit HC, Meyer MT et al. TotalSegmentator: robust segmentation of 104 anatomic structures in CT images. Radiol Artif Intell. 2023;5(5):e230024. https:\/\/doi.org\/10.1148\/ryai.230024. Published 2023 Jul 5.","journal-title":"Radiol Artif Intell"},{"issue":"2","key":"8051_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41592-020-01008-z","volume":"18","author":"F Isensee","year":"2021","unstructured":"Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self-configuring method for deep learning\u2013based biomedical image segmentation. Nat Methods. 2021;18(2):203\u201311. https:\/\/doi.org\/10.1038\/s41592-020-01008-z.","journal-title":"Nat Methods"},{"issue":"23","key":"8051_CR19","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.2217\/fon.15.267","volume":"11","author":"R Golfieri","year":"2015","unstructured":"Golfieri R, Mosconi C, Cappelli A, et al. Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma. Future Oncol. 2015;11(23):3133\u201342. https:\/\/doi.org\/10.2217\/fon.15.267.","journal-title":"Future Oncol"},{"issue":"3","key":"8051_CR20","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/liv.12574","volume":"35","author":"A Gramenzi","year":"2015","unstructured":"Gramenzi A, Golfieri R, Mosconi C, et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 2015;35(3):1036\u201347. https:\/\/doi.org\/10.1111\/liv.12574.","journal-title":"Liver Int"},{"key":"8051_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s10278-025-01716-y","author":"AP Nicoli","year":"2025","unstructured":"Nicoli AP, Bach M, Wasserthal J, et al. Liver segment and lesion segmentation on CT and MRI: an open-source contribution to totalsegmentator. J Digit Imaging Inf med. 2025. https:\/\/doi.org\/10.1007\/s10278-025-01716-y.","journal-title":"J Digit Imaging Inf med"},{"issue":"9","key":"8051_CR22","doi-asserted-by":"publisher","first-page":"djv156","DOI":"10.1093\/jnci\/djv156","volume":"107","author":"TT Chen","year":"2015","unstructured":"Chen TT. Milestone survival: a potential intermediate endpoint for immune checkpoint inhibitors. J Natl Cancer Inst. 2015;107(9):djv156. https:\/\/doi.org\/10.1093\/jnci\/djv156. Published 2015 Jun 25.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"8051_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/cancers13010090","volume":"13","author":"G Cabibbo","year":"2020","unstructured":"Cabibbo G, Celsa C, Enea M, et al. Progression-free survival early assessment is a robust surrogate endpoint of overall survival in immunotherapy trials of hepatocellular carcinoma. Cancers (Basel). 2020;13(1):90. https:\/\/doi.org\/10.3390\/cancers13010090. Published 2020 Dec 30.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"8051_CR24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00432-013-1564-4","volume":"140","author":"A Saxena","year":"2014","unstructured":"Saxena A, Bester L, Shan L, et al. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. J Cancer Res Clin Oncol. 2014;140(4):537\u201347. https:\/\/doi.org\/10.1007\/s00432-013-1564-4.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"15","key":"8051_CR25","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","volume":"34","author":"GA van Hazel","year":"2016","unstructured":"van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized Phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723\u201331. https:\/\/doi.org\/10.1200\/JCO.2015.66.1181.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8051_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jvir.2009.09.011","volume":"21","author":"BL Dunfee","year":"2010","unstructured":"Dunfee BL, Riaz A, Lewandowski RJ, et al. Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival. J Vasc Interv Radiol. 2010;21(1):90\u20135. https:\/\/doi.org\/10.1016\/j.jvir.2009.09.011.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"8051_CR27","doi-asserted-by":"publisher","first-page":"931","DOI":"10.21037\/jgo.2016.06.15","volume":"7","author":"N Bhooshan","year":"2016","unstructured":"Bhooshan N, Sharma NK, Badiyan S, et al. Pretreatment tumor volume as a prognostic factor in metastatic colorectal cancer treated with selective internal radiation to the liver using yttrium-90 resin microspheres. J Gastrointest Oncol. 2016;7(6):931\u20137. https:\/\/doi.org\/10.21037\/jgo.2016.06.15.","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"8051_CR28","first-page":"248","volume":"9","author":"SM Seraj","year":"2019","unstructured":"Seraj SM, Zadeh MZ, Werner TJ, et al. Pretreatment volumetric parameters of FDG-PET predict the survival after Yttrium-90 radio-embolization in metastatic liver disease. Am J Nucl Med Mol Imaging. 2019;9(5):248\u201354. Published 2019 Oct 15.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"9","key":"8051_CR29","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1007\/s00330-022-08737-z","volume":"32","author":"L M\u00fcller","year":"2022","unstructured":"M\u00fcller L, Kloeckner R, M\u00e4hringer-Kunz A, et al. Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC. Eur Radiol. 2022;32(9):6302\u201313. https:\/\/doi.org\/10.1007\/s00330-022-08737-z.","journal-title":"Eur Radiol"},{"issue":"2","key":"8051_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209\u201318. https:\/\/doi.org\/10.1172\/JCI24282.","journal-title":"J Clin Invest"},{"key":"8051_CR31","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.2967\/jnumed.116.173104","volume":"57","author":"S Gnesin","year":"2016","unstructured":"Gnesin S, Canetti L, Adib S, et al. Partition Model-Based 99mTc-MAA SPECT\/CT Predictive dosimetry compared with 90Y TOF PET\/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison. J Nucl Med. 2016;57:1672\u20138.","journal-title":"J Nucl Med"},{"key":"8051_CR32","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s00259-019-04465-7","volume":"47","author":"A Jadoul","year":"2020","unstructured":"Jadoul A, Bernard C, Lovinfosse P, et al. Comparative dosimetry between (99m)Tc-MAA SPECT\/CT and (90)Y PET\/CT in primary and metastatic liver tumors. Eur J Nucl Med Mol Imaging. 2020;47:828\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8051_CR33","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jvir.2016.12.1221","volume":"28","author":"P Haste","year":"2017","unstructured":"Haste P, Tann M, Persohn S, et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission CT and posttreatment positron emission tomography\/CT. J Vasc Interv Radiol. 2017;28:722\u201330. e721.","journal-title":"J Vasc Interv Radiol"},{"key":"8051_CR34","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.2967\/jnumed.115.162685","volume":"56","author":"H Ilhan","year":"2015","unstructured":"Ilhan H, Goritschan A, Paprottka P, et al. Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors. J Nucl Med. 2015;56:1654\u201360.","journal-title":"J Nucl Med"},{"key":"8051_CR35","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.2967\/jnumed.112.117614","volume":"54","author":"M Wondergem","year":"2013","unstructured":"Wondergem M, Smits ML, Elschot M, et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med. 2013;54:1294\u2013301.","journal-title":"J Nucl Med"},{"issue":"3","key":"8051_CR36","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/bjs5.50280","volume":"4","author":"K Tai","year":"2020","unstructured":"Tai K, Komatsu S, Sofue K, et al. Total tumour volume as a prognostic factor in patients with resectable colorectal cancer liver metastases. BJS Open. 2020;4(3):456\u201366. https:\/\/doi.org\/10.1002\/bjs5.50280.","journal-title":"BJS Open"},{"issue":"5","key":"8051_CR37","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1159\/000507933","volume":"9","author":"T Kumada","year":"2020","unstructured":"Kumada T, Toyoda H, Tada T, Yasuda S, Tanaka J. Changes in background liver function in patients with hepatocellular carcinoma over 30 years: comparison of child-pugh classification and albumin bilirubin grade. Liver Cancer. 2020;9(5):518\u201328. https:\/\/doi.org\/10.1159\/000507933.","journal-title":"Liver Cancer"},{"issue":"6","key":"8051_CR38","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jhep.2010.11.008","volume":"54","author":"M Bernardi","year":"2011","unstructured":"Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol. 2011;54(6):1297\u2013306. https:\/\/doi.org\/10.1016\/j.jhep.2010.11.008.","journal-title":"J Hepatol"},{"issue":"1","key":"8051_CR39","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358\u201380. https:\/\/doi.org\/10.1002\/hep.29086.","journal-title":"Hepatology"},{"issue":"11","key":"8051_CR40","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.4254\/wjh.v13.i11.1688","volume":"13","author":"MA Kalas","year":"2021","unstructured":"Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. World J Hepatol. 2021;13(11):1688\u201398. https:\/\/doi.org\/10.4254\/wjh.v13.i11.1688.","journal-title":"World J Hepatol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08051-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08051-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08051-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:32:18Z","timestamp":1790929938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08051-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8051"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08051-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Technical University of Munich, TUM Klinikum Rechts der Isar (reference 87\/18S).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for clinically indicated CT imaging, interventional procedures, and laboratory assessments was obtained as part of routine care. The requirement for additional study-specific informed consent was waived by the local ethics committee due to the retrospective study design.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. Eiber reports consultancy and\/or research support from Blue Earth Diagnostics, Novartis\/AAA, Telix, Bayer, RayzeBio, Point Biopharma, Eckert & Ziegler, Janssen Pharmaceuticals, Parexel, and Bioclinica, as well as a patent application for rhPSMA. Dr. Lange reports honoraria\/speaker fees; service on advisory boards or travel support: Taiho, AstraZeneca, Jazz, Daiichi Sankyo, Janssen-Cilag, MSD.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}